MedTrace Logo

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

NCT03241199 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-08-08

No results posted yet for this study

Summary

The purpose of this pilot study is to investigate whether some patients who were started on a 2G-TKI as first-line treatment can be safely switched to imatinib, a first-generation TKI, while maintaining or even deepening the molecular response as a cost-effective treatment. Eligible patients will be switched to imatinib 400mg daily, with regular molecular monitoring.

Conditions

  • Chronic Myeloid Leukemia
  • Philadelphia Chromosome Positive CML

Interventions

DRUG

Imatinib Mesylate

a first-generation tyrosine kinase inhibitors

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Carol Cheung, MBBS · Queen Mary Hospital, Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-06-13
Completion
2021-01-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241199 on ClinicalTrials.gov